MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*”Architects”: Geriatrics, Gerontology, Geroscience, Longevity, Healthspan & Aging
Insilico Medicine, Inc.
Organization & Developments: Insilico Medicine
Parents
Insilico Medicine, Inc.
Children
*Artificial intelligence (AI) platform for new drug development in cancer, fibrosis, immunity, central nervous system and age-related diseases.
*Platform uses next-generation AI systems that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques
2020: Pfizer Taps Insilico Medicine to Use AI for Drug Target Discovery
2022: Insilico Medicine's AI uncovers 28 new potential drug targets for ALS
2024: AACR 2024: Insilico Medicine to Present Preclinical Data for AI-Generated Cancer Drugs
2024: Insilico Medicine announces positive topline results of ISM001-055 for the treatment of idiopathic pulmonary fibrosis (IPF) developed using generative AI
2025: AI Meets Aging Inside the Longevity Revolution with Insilico Medicine (Part 1)
2025: AI Meets Aging Inside The Longevity Revolution with Insilico Medicine (Part 2)
2025: Insilico, U. Toronto Researchers Develop Quantum-Classical Computing AI Model
2026: AI drug discovery company finds potential non-opioid pain medication in Abu Dhabi lab
2026: AI-designed drug candidate reverses biological age in clinical study
Jumps
Finance & Acquisitions: Insilico Medicine
Key People: Insilico Medicine